$BEAT News: HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio
First patent significantly advances intellectual property for HeartBeam’s credit card-sized ECG device, bolstering both the defensive and offensive moat around the company’s core technology
Second patent expands the use of risk-based diagnostic algorithms into HeartBeam’s product portfolio around wearable devices
HeartBeam now has 20 issued patents worldwide, cementing Company’s leadership in cardiac monitoring innovation
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling future product extensions. The patents reinforce HeartBeam’s groundbreaking innovations and further solidify the Company’s intellectual property (IP) footprint in cardiac monitoring technology that bring advanced cardiac insights to patients and clinicians.
The first patent protects IP around HeartBeam’s credit card-sized, cable-free 3D ECG device. Designed for ease of use, the device features chest and finger electrodes to capture high-fidelity electrical signals in 3D (by capturing 3 non-coplanar directions) – enabling patients to record their symptoms the moment they occur, wherever they are. The signals are then synthesized into a familiar 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is currently under review with the FDA. Data from the VALID-ECG pivotal study supporting the FDA submission was presented at the Heart Rhythm Society conference in April 2025.
The second patent protects HeartBeam’s rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. Designed to operate on any cardiac monitoring system including wearables, the algorithm enables risk-based escalation by detecting anomalies during passive monitoring and prompting the user to collect high-fidelity 3D ECG signals with HeartBeam’s credit card-sized device, enabling synthesis of a 12-lead ECG.
“HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility. The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care,” said Robert Eno, Chief Executive Officer of HeartBeam.
With these two new U.S. patents, HeartBeam now holds 20 issued US and international patents, as well as 2 allowed patents and 32 pending patents, adding to an already robust IP portfolio that supports the company’s differentiated position in remote cardiac diagnostics. These innovations lay the groundwork for future capabilities such as AI-driven classification algorithms and ischemia detection, further extending HeartBeam’s potential to provide unprecedented cardiac insights to individuals and physicians.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-co-planar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The Company holds 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
https://cts.businesswire.com/ct/CT?id=bwnews&...mp;lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506303008/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
First patent significantly advances intellectual property for HeartBeam’s credit card-sized ECG device, bolstering both the defensive and offensive moat around the company’s core technology
Second patent expands the use of risk-based diagnostic algorithms into HeartBeam’s product portfolio around wearable devices
HeartBeam now has 20 issued patents worldwide, cementing Company’s leadership in cardiac monitoring innovation
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the addition of two new U.S. patents, reinforcing its core intellectual property position and enabling future product extensions. The patents reinforce HeartBeam’s groundbreaking innovations and further solidify the Company’s intellectual property (IP) footprint in cardiac monitoring technology that bring advanced cardiac insights to patients and clinicians.
The first patent protects IP around HeartBeam’s credit card-sized, cable-free 3D ECG device. Designed for ease of use, the device features chest and finger electrodes to capture high-fidelity electrical signals in 3D (by capturing 3 non-coplanar directions) – enabling patients to record their symptoms the moment they occur, wherever they are. The signals are then synthesized into a familiar 12-lead ECG using a personalized transformational matrix. The 12-lead ECG synthesis software is currently under review with the FDA. Data from the VALID-ECG pivotal study supporting the FDA submission was presented at the Heart Rhythm Society conference in April 2025.
The second patent protects HeartBeam’s rhythm analysis algorithm, which distinguishes between sinus rhythm, atrial fibrillation, and other arrhythmias using continuous signal input. Designed to operate on any cardiac monitoring system including wearables, the algorithm enables risk-based escalation by detecting anomalies during passive monitoring and prompting the user to collect high-fidelity 3D ECG signals with HeartBeam’s credit card-sized device, enabling synthesis of a 12-lead ECG.
“HeartBeam’s vision is to make it easier for patients and physicians to monitor and diagnose cardiac symptoms outside of a medical facility. The new patents add to our growing IP portfolio, enabling us to expand the reach and impact of our groundbreaking 3D ECG technology as we strive to transform the future of cardiac care,” said Robert Eno, Chief Executive Officer of HeartBeam.
With these two new U.S. patents, HeartBeam now holds 20 issued US and international patents, as well as 2 allowed patents and 32 pending patents, adding to an already robust IP portfolio that supports the company’s differentiated position in remote cardiac diagnostics. These innovations lay the groundwork for future capabilities such as AI-driven classification algorithms and ischemia detection, further extending HeartBeam’s potential to provide unprecedented cardiac insights to individuals and physicians.
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first ever cable-free device capable of collecting ECG signals in 3D, from 3 non-co-planar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The Company holds 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.
Forward-Looking Statements
All statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at www.sec.gov. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
https://cts.businesswire.com/ct/CT?id=bwnews&...mp;lang=en
View source version on businesswire.com: https://www.businesswire.com/news/home/20250506303008/en/
Investor Relations Contact:
Chris Tyson
Executive Vice President
MZ North America
Direct: 949-491-8235
BEAT@mzgroup.us
www.mzgroup.us
Media Contact:
media@heartbeam.com
Source: HeartBeam, Inc.
